Stock Titan’s Post

The first results from the platform trial MND-SMART, led by UK DRI Director Prof Siddharthan Chandran, Prof Suvankar Pal, and the Euan MacDonald Centre for Motor Neuron Disease Research at the University of Edinburgh, have been reported in the Lancet Neurology. The trial aims to significantly speed up delivery of new treatments for motor neuron disease (MND). Memantine and trazodone were tested & found not to be effective compared with placebo - but the innovative trial design has halved the time taken to test these treatments. Prof Siddharthan Chandran said: “There is an urgent need for new treatments for people affected by MND. Through MND-SMART, we have halved the time taken to conclusively test two drugs, showing the trial is doing exactly what it set out to. Momentum is gathering, and I am hopeful that this approach will, in time, deliver effective, disease-modifying treatments for people with MND.” Read the full story ⬇️

Excited to share our new paper in Frontiers in Neurology which was published today. The paper, titled “Spectris™ Treatment Preserves Corpus Callosum Structure in Alzheimer’s Disease,” highlights the potential of Cognito’s Spectris™ as a disease-modifying candidate for #Alzheimer’s disease (AD). 🧠🧠 This is the first study to report on the ability of Spectris to preserve the corpus callosum in patients with mild to moderate Alzheimer’s disease. The corpus callosum is responsible for information transfer between the brain's hemispheres and plays a crucial role in maintaining #cognitive function. “The results highlight that preserving the structural integrity of the brain’s communication pathways could potentially slow cognitive decline and improve daily functioning,” said Ralph Kern, M.D., MHSc, Chief Medical Officer at Cognito Therapeutics. “This study supports Spectris as a potential disease-modifying therapy in Alzheimer’s, providing a different treatment modality beyond traditional drug-based approaches. Read the full release: https://lnkd.in/eEEhHdPy

It's incredibly gratifying to witness the realization of an idea I've been advocating for publicly over the years. The concept was to counteract the resistance to levodopa, a cost-effective treatment for the initial symptoms of Parkinson's disease, by introducing a skin patch or subcutaneous injection. This approach aimed to circumvent the inactivation of levodopa by gut microbes, presenting a strategic solution to a longstanding issue. The recent success of Neuroderm's positive phase 3 results, aligning with this very principle, marks a significant milestone in the field. #parkinson #neuroscience #neurology #neuroderm #Mitsubishitanabe

A recent study in JAMA Neurology found that fecal microbiota transplantation (FMT) does not provide clinically meaningful improvements for Parkinson's disease (PD). Researchers led by Dr. Filip Scheperjans from Helsinki University Hospital studied 47 PD patients, assigning them randomly to receive FMT or a placebo. After six months, changes in Parkinson's disease symptoms, measured by the Movement Disorder Society Unified Parkinson's Disease Rating Scale, showed no significant difference between the groups. The FMT group experienced more gastrointestinal adverse events (16 vs. 1). Surprisingly, the placebo group saw a stronger increase in dopaminergic medication and better motor and nonmotor outcomes. Microbiota changes were more pronounced after FMT but varied by donor, while the placebo group more frequently reversed dysbiosis status. The authors suggest further studies to explore modified FMT approaches, bowel cleansing, and the impact of donor microbiota composition on PD outcomes and medication needs. #neurology #parkinsons #microbiota With the Specialist combines artificial intelligence with a board certified neurologist to enhance neurological care in the primary care setting, bringing the neurology consult to you. #withthespecialist #aiinhealthcare #innovation https://lnkd.in/gHR9wwt5 https://lnkd.in/gExrwg2P

“Cognivue Clarity® in the Detection of Biomarker-Confirmed Mild Cognitive Impairment and Alzheimer’s Disease” was a poster presented at the American Academy of Neurology (AAN) Annual Meeting in April. The data has been published in Neurology, Volume 102, Number 17 Supplement 1, April 09, 2024. Key Findings: Cognivue Clarity® discriminated healthy controls from those with Mild Cognitive Impairment (MCI) and Alzheimer’s disease (AD), strongly correlated with AD biomarkers, and had strong psychometric properties. The Bio-Hermes study, funded by the Global Alzheimer's Platform Foundation, enrolled healthy controls, as well as patients with MCI and AD. Assessments included sociodemographics, Cognivue Clarity, plasma AD biomarkers, and amyloid positron emission tomography (PET) scans. Cognivue Clarity’s psychometric properties, diagnosis discrimination, correlations with AD biomarkers, and diagnostic power were analyzed. Journal Publication: https://bit.ly/3Jw6l2s Link to see the poster: https://bit.ly/3JsUORg #alzheimersdisease #alzheimers #ad #mildcognitiveimpairement #cognitivehealth #earlydetection #cognitivetesting #dca #biomarkers #biohermes #AANAM Cognivue, Inc.

Top Studies in Neurology From 2023: New Drugs in Alzheimer's: Monoclonal antibodies against beta amyloid for the treatment of early Alzheimer's disease. - For two monoclonal antibodies, lecanemab and donanemab, there was efficacy in slowing the disease progression. - But in practical terms, these two treatments pose significant problems . First ; For diagnosis, you need PET-CT. Second ; The therapy has to be done via IV regularly, every 2 weeks or every 4 weeks. Along side number of side effects , which need MRI control , and the high cost of the treatment . - We have, at present, no infrastructure for treating these patients. We also have a number of monoclonal antibodies that were not effective. _Hans-Christoph Diener, MD,PhD_ the medical faculty of University Duisburg-Essen in Germany

I’m thrilled to start the year off right by sharing our latest research on mitotherapy as a potential therapeutic strategy for chemotherapy-induced painful neuropathy. Oxaliplatin, a powerful antineoplastic agent, is unfortunately limited by painful peripheral neuropathy. Our findings suggest that mitotherapy could be a game-changer in pain management for patients undergoing oxaliplatin treatment. #Neuroscience #Research #PainManagement #Mitotherapy #OIPN #Oxaliplatin #NeuropathyRelief 🧠💊 Claudia Figueiredo Robson da Costa 📚 Read the Full Manuscript:

🧠 How are you leveraging biomarkers like GFAP and p-Tau 231? Linked with conditions from Alzheimer’s to TBI, these markers offer insights into neurological research. Explore neurology biomarkers and their applications in research. #Neurology #Biomarkers

📢 Key Findings from Recent Research on TNF Inhibitors and CNS Disease Risk A new systematic review and meta-analysis published in JAMA Neurology reveals an important consideration for the use of TNF inhibitors in autoimmune diseases: 🔹 36% Increased Risk of CNS Inflammatory Diseases: TNF inhibitors, commonly used to treat autoimmune diseases like rheumatoid arthritis and inflammatory bowel disease, are associated with a higher risk of developing inflammatory central nervous system (CNS) diseases, particularly demyelinating disorders such as multiple sclerosis. 🔹 Risk is Consistent Across Diseases and Inhibitors: The increased risk does not vary significantly between different autoimmune diseases or types of TNF inhibitors. 🔹 Clinical Implication: While TNF inhibitors are highly effective for managing autoimmune diseases, clinicians should be aware of this elevated risk and monitor for signs of CNS complications in patients on these therapies. Read more about the full study and its findings to stay updated on this evolving area of research! #Neuroinflammation #AutoimmuneDiseases #Neurology #TNFInhibitors #CNS #MultipleSclerosis #ClinicalResearch #Rheumatology

AstraZeneca Case Series Shows Long-Term Efficacy and Convenience of Ravulizumab in Generalized Myasthenia Gravis #neurology NeurologyLive https://lnkd.in/gWdHebPN